Ignite Creation Date:
2024-05-06 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 2:21 PM
Study NCT ID:
NCT05175274
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-03-21
First Post:
2021-12-14
Brief Title:
Colchicine Use for Primary Prevention of Coronary Artery Disease
Sponsor:
Qingdao Central Hospital
Organization:
Qingdao Central Hospital
Study Overview
Official Title:
Colchicine Use for Primary Prevention in People at High Risk of Coronary Artery Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Colchicine has been widely used as an anti-gout medicine in the past decades Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism However the effect on primary prevention has not been observed sufficiently The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None